• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Can warfarin randomized trials be reproduced in 'real life'? Adherence to warfarin guidelines for intensity of anticoagulation in a university-based warfarin clinic.

作者信息

Malik A K, Taylor A J

机构信息

Department of Medicine, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA.

出版信息

South Med J. 2000 Jan;93(1):58-61.

PMID:10653067
Abstract

BACKGROUND

Subjects in clinical trials may benefit from the increased attention and specific focus of the trial, thereby limiting the external validity of clinical trial results to clinical practice. Our study evaluated adherence to guidelines for intensity of anticoagulation in a large, university-based warfarin clinic to assess the generalizability of randomized clinical trials of warfarin efficacy to clinical practice.

METHODS

We reviewed anticoagulation clinic records of 480 patients observed for up to 2 years to determine the amount of time anticoagulation was within the recommended therapeutic range.

RESULTS

The most common indication for warfarin use was atrial arrhythmia (51.5%). Overall, anticoagulation was within the intended international normalized ratio (INR) target range on 57.8% of treatment days. Nontherapeutic treatment days were due more commonly to subtherapeutic INR values (27.6+/-25.7%) than supratherapeutic INR values (14.9+/-17.0%). This pattern was seen across all warfarin indications.

CONCLUSION

These data are comparable to those reported from large randomized trials and thus support the generalizability of clinical trials of long-term warfarin anticoagulation to clinical practice.

摘要

相似文献

1
Can warfarin randomized trials be reproduced in 'real life'? Adherence to warfarin guidelines for intensity of anticoagulation in a university-based warfarin clinic.
South Med J. 2000 Jan;93(1):58-61.
2
Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population.华法林依从性辅助工具对市中心抗凝门诊患者抗凝控制的影响。
Ann Pharmacother. 2009 Jul;43(7):1165-72. doi: 10.1345/aph.1L707. Epub 2009 Jun 23.
3
Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.华法林治疗稳定患者亚治疗剂量抗凝的血栓栓塞后果:低国际标准化比值(INR)研究
Pharmacotherapy. 2008 Aug;28(8):960-7. doi: 10.1592/phco.28.8.960.
4
Search for predictors of nontherapeutic INR results with warfarin therapy.寻找华法林治疗中INR结果无治疗效果的预测因素。
Ann Pharmacother. 2005 Dec;39(12):1996-2002. doi: 10.1345/aph.1E381. Epub 2005 Nov 15.
5
Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic.在门诊抗凝诊所进行的心房颤动抗凝治疗开放标签前瞻性研究的结果。
Clin Ther. 2004 Sep;26(9):1470-8. doi: 10.1016/j.clinthera.2004.09.002.
6
Quality of anticoagulation care in patients discharged from a pharmacist-managed anticoagulation clinic after stabilization of warfarin therapy.华法林治疗稳定后从药剂师管理的抗凝门诊出院患者的抗凝治疗质量。
Pharmacotherapy. 2008 Jan;28(1):20-6. doi: 10.1592/phco.28.1.20.
7
Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study.临床环境中房颤患者华法林治疗的抗凝控制质量及监测成本:一项多中心管理式医疗研究
Ann Pharmacother. 2005 Mar;39(3):446-51. doi: 10.1345/aph.1E169. Epub 2005 Feb 8.
8
[Anticoagulation treatment in real-life practice of patient with nonvalvular atrial fibrillation in Beijing city].[北京市非瓣膜性心房颤动患者现实生活中的抗凝治疗]
Zhonghua Yi Xue Za Zhi. 2007 Sep 4;87(33):2328-31.
9
Factors affecting medication adherence and anticoagulation control in Korean patients taking warfarin.影响服用华法林的韩国患者药物依从性和抗凝控制的因素。
J Cardiovasc Nurs. 2011 Nov-Dec;26(6):466-74. doi: 10.1097/JCN.0b013e31820914e7.
10
Self-management of anticoagulation.抗凝的自我管理。
Expert Rev Cardiovasc Ther. 2008 Aug;6(7):979-85. doi: 10.1586/14779072.6.7.979.

引用本文的文献

1
Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.维生素 K 拮抗剂控制质量与心房颤动患者结局的关系:一项荟萃分析和荟萃回归。
Thromb J. 2014 Jun 24;12:14. doi: 10.1186/1477-9560-12-14. eCollection 2014.
2
Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.心房颤动和静脉血栓栓塞研究中报告的维生素K拮抗剂控制措施:一项系统评价。
BMJ Open. 2014 Jun 20;4(6):e005379. doi: 10.1136/bmjopen-2014-005379.
3
Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data.
芬兰心房颤动患者的华法林治疗:基于初级医疗保健数据的回顾性登记研究。
BMJ Open. 2014 Feb 27;4(2):e004071. doi: 10.1136/bmjopen-2013-004071.
4
Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry.应用慢性口服抗凝剂治疗 ST 段抬高型心肌梗死患者的管理和结局:GRACE 注册研究结果。
Eur Heart J Acute Cardiovasc Care. 2013 Sep;2(3):280-91. doi: 10.1177/2048872613483019.
5
New approaches to anticoagulation in atrial fibrillation.心房颤动抗凝治疗的新方法。
Curr Cardiol Rep. 2004 Sep;6(5):354-64. doi: 10.1007/s11886-004-0038-3.
6
A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation.一项关于口服抗凝治疗有效性所报告结局指标的系统评价。
J Clin Pathol. 2003 Jan;56(1):48-51. doi: 10.1136/jcp.56.1.48.